The Future Oncology Executive: Why Clinical Judgment Alone Is No Longer Enough

If you had asked me early in my career what made a great oncology executive, my answer probably would have been simple: clinical expertise. After all, who better to lead oncology programs than someone who deeply understands the disease, the patients, and the science underlying it?

While I still firmly believe clinical expertise is the foundation of effective leadership, after nearly two decades in oncology drug development, I’ve also come to realize that this isn’t enough anymore. Modern oncology has become too interconnected, too fast-paced, and too complex for clinical knowledge alone to carry an organization forward.

Today’s oncology executives are expected to understand science, but they’re also expected to think strategically, navigate uncertainty, build high-performing teams, communicate across disciplines, and make decisions that influence not just one study, but an entire portfolio. The executive role has evolved and I think that’s one of the most important leadership shifts happening in our industry.

The Best Executives Don’t Just Understand the Drug

One of the biggest changes I’ve noticed is that successful oncology executives no longer spend all of their time thinking about the molecule. Instead, they’re thinking about the ecosystem surrounding it. They ask questions such as: Can this trial realistically enroll participants? Is the chosen biomarker strategy practical? Can manufacturing scale if the data are positive? Will investigators adopt the protocol? How will regulators view this endpoint? What does the competitive landscape look like by the time this study concludes? Will payers see enough value in the findings? How quickly can we generate meaningful evidence?

These questions go beyond departmental boundaries and encompass business, scientific, operational, and leadership considerations. The executive’s role is to effectively connect these diverse aspects.

Clinical Judgment Remains the Anchor

Despite these significant changes, one aspect that I firmly believe will never lose its value is clinical judgment. While technology can organize information, artificial intelligence can summarize data, clinical judgment remains the cornerstone of effective decision-making in oncology. Analytics can identify trends, but none of these tools can replace the ability to interpret medicine through the lens of experience. 

Clinical judgment is what allows leaders to recognize when an eligibility criterion is too restrictive, when a safety signal deserves immediate attention, when an investigator’s concern reflects something larger than an isolated event, and when emerging data should change a development strategy. 

The future executive won’t rely less on clinical judgment; they’ll rely on it differently, making it the foundation for every strategic decision that follows.

Strategy Begins Where Medicine Ends

Over the years, I’ve learned that there comes a point in every discussion where medicine alone cannot provide the answer. Should we expand into another indication? Should we pursue accelerated approval? Should we amend the protocol? Should we continue development? Should we partner or develop independently? Should we invest additional resources now or prioritize another asset? 

Clinical data inform these decisions, but they don’t make them. That’s where strategic thinking becomes essential. Great executives know how to translate medical evidence into organizational direction, a skill that goes beyond simply interpreting data.

The Executive’s Job Is Becoming More Cross-Functional Every Year

When I look at the strongest oncology leaders I’ve worked with, one characteristic consistently stands out. They’re remarkably comfortable crossing disciplines. They can move from discussing dose-limiting toxicities to manufacturing timelines, from biomarker strategy to investor expectations, from protocol amendments to commercial positioning. Not because they’re experts in every field, but because they understand how each discipline influences the others. 

This is becoming one of the defining leadership skills in biotechnology. Organizations no longer succeed because departments perform well independently; they succeed because those departments move together.

Decision-Making Is Becoming a Competitive Advantage

The pace of oncology development has accelerated dramatically, leading to the emergence of new competitors, changing standards of care, scientific discoveries reshaping treatment landscapes, and evolving regulatory pathways. As a result, waiting for perfect information is becoming increasingly costly.

I’ve come to believe that one of the defining characteristics of successful executives is decision quality. This means making thoughtful decisions before certainty arrives, even when it’s uncomfortable. This is the reality of innovation. Leadership isn’t about eliminating uncertainty; it’s about helping organizations move forward despite it.

Communication Is No Longer a Soft Skill

For years, communication was often described as an important leadership skill. However, today, I’d describe it as a strategic capability. Modern oncology development depends on alignment among various groups, including sponsors, investigators, medical monitors, clinical operations, manufacturing, regulatory affairs, and executive leadership. If these groups aren’t aligned, even excellent science can lose momentum.

The best executives I’ve observed aren’t simply strong communicators; they’re translators. They can explain scientific complexity to boards, operational realities to investors, strategic priorities to development teams, and clinical uncertainty to regulators. This ability creates trust, which accelerates execution.

The Future Executive Must Be Comfortable With Continuous Learning

As the pace of innovation continues to accelerate, executives must be willing to learn and adapt to new challenges and opportunities. Perhaps the greatest challenge for oncology executives is the field’s relentless pace of change. Science, technology, regulatory expectations, competitive landscapes, and even leadership itself are constantly evolving. This means that expertise, once acquired, must be continuously maintained.

I’ve found that the most effective leaders share a common trait: curiosity. They actively seek knowledge by asking questions, reading broadly, and embracing perspectives beyond their own expertise. They are confident enough to acknowledge their limitations and welcome disagreement. Ironically, this is often what makes people trust them most.

Artificial Intelligence Will Raise the Bar for Leadership

There’s no question that AI will become deeply integrated into oncology drug development. This will lead to faster routine analysis, easier access to information, and more efficient administrative work. However, I don’t believe this diminishes the executive role; rather, it elevates it. When everyone has access to similar information, competitive advantage shifts toward judgment, prioritization, vision, culture, decision-making, and more.

The future executive won’t be the person with the most information; they’ll be the one who consistently makes the best decisions with it.

Building Leaders, Not Just Organizations

One area I hope we’ll dedicate more time to discussing over the next decade is leadership development.

We do an excellent job in training physicians to diagnose diseases, scientists to discover therapies, statisticians to analyze data, and operational teams to execute studies. However, we spend significantly less time to preparing individuals to lead across these disciplines. This has to change. 

The next generation of oncology executives won’t simply inherit more complex organizations. They’ll inherit a faster, more interconnected industry than any generation before them. Preparing them requires more than technical education; it requires intentional leadership development.

A Final Thought

When I think about the future of oncology executives, I don’t envision someone sitting at the head of  a conference table making isolated decisions. Instead, I picture individuals who seamlessly connect science with strategy, medicine with operations, innovation with execution, and people with purpose. While clinical judgment will always serve as the foundation of decision-making, it alone is no longer sufficient. 

The leaders who will shape the next era of oncology will possess a profound understanding of organizations, people, and the long-term impact of decisions made today on therapies that may not reach patients for years. This is a different kind of leadership than our industry needed twenty years ago. It’s broader, more collaborative, and strategically focused. 

In my opinion, it’s also more exciting than ever. The future of oncology won’t be solely determined by breakthrough therapies; It will be shaped by leaders capable of turning those breakthroughs into better outcomes for patients around the world.

-The Medical Monitor’s Desk